Milestone Pharmaceuticals Inc. (MIST) · INSIDERData sourcesSEC Form 49m ago
House PTR9m ago
SEC 13F8m ago
Robinhood Chain8m ago
Public companyMilestone Pharmaceuticals Inc.
MISTCIK 0001408443
Price$0.76
1 year-57.6%
Disclosed transactions30
Buys / sells0 / 8
Max Insider Score66
Connections with evidence6
MIST · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 9 | | MISTMilestone Pharmaceuticals Inc. Grant or award | A | — 77.0K sh | Jun 10, 2026 | Jun 12, 2026 |
| 5 | BDBharucha DavidChief Medical Officer | MISTMilestone Pharmaceuticals Inc. Grant or award | A | — 204.0K sh | Feb 2, 2026 | Feb 4, 2026 traded Feb 2, 2026 | +2d | SEC Form 4 | |
| 5 | BDBharucha DavidChief Medical Officer | MISTMilestone Pharmaceuticals Inc. Grant or award | A | — 136.0K sh | Feb 2, 2026 | Feb 4, 2026 traded Feb 2, 2026 | +2d | SEC Form 4 | |
| 5 | NENelson Jeffrey EdwardChief Operating Officer | MISTMilestone Pharmaceuticals Inc. Grant or award | A | — 204.0K sh | Feb 2, 2026 | Feb 4, 2026 traded Feb 2, 2026 | +2d | SEC Form 4 | |
| 5 | NENelson Jeffrey EdwardChief Operating Officer | MISTMilestone Pharmaceuticals Inc. Grant or award | A | — 136.0K sh | Feb 2, 2026 | Feb 4, 2026 traded Feb 2, 2026 | +2d | SEC Form 4 | |
| 24 | BDBharucha DavidChief Medical Officer | MISTMilestone Pharmaceuticals Inc. Grant or award | A | — 100.0K sh | Dec 12, 2025 | Jan 28, 2026 traded Dec 12, 2025 | +47d | SEC Form 4 | |
| 17 | BDBharucha DavidChief Medical Officer | MISTMilestone Pharmaceuticals Inc. Option exercise | M | — 20.1K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 24 | HAHasija AmitCFO & EVP of Corp. Development | MISTMilestone Pharmaceuticals Inc. Grant or award | A | — 100.0K sh | Dec 12, 2025 | Jan 28, 2026 traded Dec 12, 2025 | +47d | SEC Form 4 | |
| 24 | MLMuller LorenzChief Commercial Officer | MISTMilestone Pharmaceuticals Inc. Grant or award | A | — 100.0K sh | Dec 12, 2025 | Jan 28, 2026 traded Dec 12, 2025 | +47d | SEC Form 4 | |
| 17 | MLMuller LorenzChief Commercial Officer | MISTMilestone Pharmaceuticals Inc. Option exercise | M | — 20.1K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 36 | HAHasija AmitCFO & EVP of Corp. Development | MISTMilestone Pharmaceuticals Inc. Open-market sale | SELL | $24K 12.2K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 13 | HAHasija AmitCFO & EVP of Corp. Development | MISTMilestone Pharmaceuticals Inc. Option exercise | M | — 20.1K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 36 | HAHasija AmitCFO & EVP of Corp. Development | MISTMilestone Pharmaceuticals Inc. Grant or award | A | — 100.0K sh | Dec 12, 2025 | Jan 28, 2026 traded Dec 12, 2025 | +47d | SEC Form 4 | |
| 24 | NENelson Jeffrey EdwardChief Operating Officer | MISTMilestone Pharmaceuticals Inc. Grant or award | A | — 100.0K sh | Dec 12, 2025 | Jan 28, 2026 traded Dec 12, 2025 | +47d | SEC Form 4 | |
| 17 | NENelson Jeffrey EdwardChief Operating Officer | MISTMilestone Pharmaceuticals Inc. Option exercise | M | — 20.1K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 36 | MLMuller LorenzChief Commercial Officer | MISTMilestone Pharmaceuticals Inc. Open-market sale | SELL | $22K 11.2K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 62 | HAHasija AmitCFO & EVP of Corp. Development | MISTMilestone Pharmaceuticals Inc. Open-market sale | SELL | $135K 58.0K sh | Dec 15, 2025 | Jan 28, 2026 traded Dec 15, 2025 | +44d | SEC Form 4 | |
| 62 | MLMuller LorenzChief Commercial Officer | MISTMilestone Pharmaceuticals Inc. Open-market sale | SELL | $124K 53.6K sh | Dec 15, 2025 | Jan 28, 2026 traded Dec 15, 2025 | +44d | SEC Form 4 | |
| 36 | NENelson Jeffrey EdwardChief Operating Officer | MISTMilestone Pharmaceuticals Inc. Open-market sale | SELL | $24K 12.2K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 62 | BDBharucha DavidChief Medical Officer | MISTMilestone Pharmaceuticals Inc. Open-market sale | SELL | $135K 58.0K sh | Dec 15, 2025 | Jan 28, 2026 traded Dec 15, 2025 | +44d | SEC Form 4 | |
| 9 | BDBharucha DavidChief Medical Officer | MISTMilestone Pharmaceuticals Inc. Option exercise | M | — 20.1K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 9 | MLMuller LorenzChief Commercial Officer | MISTMilestone Pharmaceuticals Inc. Option exercise | M | — 20.1K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 17 | HAHasija AmitCFO & EVP of Corp. Development | MISTMilestone Pharmaceuticals Inc. Option exercise | M | — 20.1K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 36 | MLMuller LorenzChief Commercial Officer | MISTMilestone Pharmaceuticals Inc. Grant or award | A | — 100.0K sh | Dec 12, 2025 | Jan 28, 2026 traded Dec 12, 2025 | +47d | SEC Form 4 | |
| 66 | NENelson Jeffrey EdwardChief Operating Officer | MISTMilestone Pharmaceuticals Inc. Open-market sale | SELL | $135K 58.0K sh | Dec 15, 2025 | Jan 28, 2026 traded Dec 15, 2025 | +44d | SEC Form 4 | |
| 13 | NENelson Jeffrey EdwardChief Operating Officer | MISTMilestone Pharmaceuticals Inc. Option exercise | M | — 20.1K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 36 | BDBharucha DavidChief Medical Officer | MISTMilestone Pharmaceuticals Inc. Grant or award | A | — 100.0K sh | Dec 12, 2025 | Jan 28, 2026 traded Dec 12, 2025 | +47d | SEC Form 4 | |
| 24 | NENelson Jeffrey EdwardChief Operating Officer | MISTMilestone Pharmaceuticals Inc. Grant or award | A | — 100.0K sh | Dec 12, 2025 | Jan 28, 2026 traded Dec 12, 2025 | +47d | SEC Form 4 | |
| 36 | BDBharucha DavidChief Medical Officer | MISTMilestone Pharmaceuticals Inc. Open-market sale | SELL | $24K 12.2K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 16 | MLMuller LorenzChief Commercial Officer | MISTMilestone Pharmaceuticals Inc. Gift | G | — 25.0K sh | Dec 9, 2025 | Dec 11, 2025 traded Dec 9, 2025 | +2d | SEC Form 4 | |
CFO & EVP of Corp. Development · Jan 28, 2026